Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Allscripts Healthcare Solutions Inc (MDRX) Solutions: Worth A Shot? – Cerner Corporation (CERN)

Prime takeover candidate: The market for electronic medical records is extremely crowded and ripe for takeover bids. Through its third quarter last year, Allscripts has continued to express guarded interest in a sale. The right acquisition would do much to give it a fresh start.

On the flip side:

Lack of direction:  With continuing changes in governance at the top, Allscripts doesn’t look like a company that knows where it’s going. That leaves it open to slashing attacks in hospital boardrooms by other vendors, who are, I can guarantee you, telling CEOs that Allscripts is too wobbly to be a steady partner.

Sagging income: Allscripts lost ground in its third quarter ended Sept. 30, 2012, with $360.7 million in revenue falling slightly below 2011’s $363.7 million. More troublingly, Allscripts net income fell from $19.1 million, or $0.10 per share, in Q3 2011 to of $9.2 million, or $0.05 per share in Q3 2012.

So, is Allscripts worth a shot? Despite the troubles at the top and the admittedly shaky income numbers, I can’t see Allscripts doing worse and it could do a lot better (particularly if a well-financed competitor buys it, which I see as a strong possibility).  Allscripts has a product with market traction, a history with buyers, resources and — from what I see — it’s gotten over the worst of the gyrations which made its 2012 such a colorful year.  While I don’t anticipate immediate gains, I think Allscripts still has good mid-term potential and expect to see it either thrive or be acquired this year.

The article Allscripts Healthcare (NASDAQ:MDRX) Solutions: Worth A Shot? originally appeared on Fool.com and is written by Anne Zieger.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.